Evidence map›Paper›PMID 40381058›Full record

Trial reportInternational ophthalmology2025

Combining ranibizumab with calcium dobesilate to reduce injection frequency in diabetic macular edema treatment.

Jian-Ying Chen, Hong-Wei Pan, Xiao-Ming Zhang, Jing-Min Liu, Sum-Yuet Chan, Ting-Ting Liu, Jian-Yi Ma, Qi Liu, Wan-Zhao Yi, Ya-Ni Wu and 3 more

Abstract readRandomized Controlled TrialComparative Study
PubMed Publisher
In one paragraph

Trial report in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jian-Ying ChenDepartment of Ophthalmology, The First Affiliated Hospital, Jinan University, Guangzhou, 510632, China.
Hong-Wei PanDepartment of Ophthalmology, The First Affiliated Hospital, Jinan University, Guangzhou, 510632, China.
Xiao-Ming ZhangDepartment of Ophthalmology, Guangdong Women and Children Hospital, Guangzhou, China.
Jing-Min LiuDepartment of Ophthalmology, The First Affiliated Hospital, Jinan University, Guangzhou, 510632, China.
Sum-Yuet ChanDepartment of Ophthalmology, The First Affiliated Hospital, Jinan University, Guangzhou, 510632, China.
Ting-Ting LiuDepartment of Ophthalmology, The First Affiliated Hospital, Jinan University, Guangzhou, 510632, China.
Jian-Yi MaDepartment of Ophthalmology, The First Affiliated Hospital, Jinan University, Guangzhou, 510632, China.
Qi LiuInstitute of Ophthalmology, School of Medicine, Jinan University, Guangzhou, China.
Wan-Zhao YiInstitute of Ophthalmology, School of Medicine, Jinan University, Guangzhou, China.
Ya-Ni WuInstitute of Ophthalmology, School of Medicine, Jinan University, Guangzhou, China.
Shuo-Shuo GuInstitute of Ophthalmology, School of Medicine, Jinan University, Guangzhou, China.
Ling-Xiao XiaInstitute of Ophthalmology, School of Medicine, Jinan University, Guangzhou, China.
Jing MengDepartment of Ophthalmology, The First Affiliated Hospital, Jinan University, Guangzhou, 510632, China. 37970860@qq.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study explores the potential of calcium dobesilate combined with intravitreal ranibizumab injections to reduce the treatment frequency in patients with DME-induced visual impairment and observes the clinical outcomes.

methodsIn this investigation involving 90 DME patients, a comparative analysis was conducted between a group treated with both ranibizumab injections and calcium dobesilate capsules (45 patients) and a control group receiving only the injections (45 patients). Treatment was monthly for 3 months, then adjusted as needed, with a follow-up at 12 months focusing on injection frequency, BCVA scores, and CMT to assess both treatment efficacy and safety.

resultsIn the 12-month trial, subjects receiving a new combination therapy experienced fewer required intravitreal injections (average 4.73) compared to those on standard monotherapy (average 6.02), showing a significant reduction (p < 0.05). Final assessments revealed substantial improvements in best corrected visual acuity (BCVA) and central macular thickness (CMT) for both groups from baseline (p < 0.05). The experimental group notably showed greater enhancements in BCVA and CMT, highlighting the superior effectiveness of the combination therapy in managing DME symptoms with reduced treatment frequency.

conclusionCombination therapy with calcium dobesilate and ranibizumab decreased the frequency of intravitreal injections and led to greater improvements in BCVA and CMT compared to ranibizumab alone over 12 months. Both treatments were well-tolerated, with the combination therapy demonstrating a favorable safety profile.

Indexed as

Calcium DobesilateDiabetic RetinopathyMacular EdemaRanibizumabVisual AcuityAgedAngiogenesis InhibitorsDrug Therapy, CombinationFemaleFollow-Up StudiesHumansIntravitreal InjectionsMacula LuteaMaleMiddle AgedTomography, Optical CoherenceAngiogenesis InhibitorsCalcium DobesilateRanibizumabVascular Endothelial Growth Factor ACalcium dobesilateDiabetic macular edemaEfficacyIntravitreal injectionsRanibizumab

Identifiers

PMID40381058

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.